Alok A Khorana1, Charles W Francis2, Nicole M Kuderer3, Marc Carrier4, Thomas L Ortel5, Ted Wun6, Deborah Rubens2, Susan Hobbs2, Renuka Iyer7, Derick Peterson2, Andrea Baran2, Katherine Kaproth-Joslin2, Gary H Lyman8. 1. Cleveland Clinic, Cleveland, OH, USA. Electronic address: Khorana@ccf.org. 2. University of Rochester, Rochester, NY, USA. 3. University of Washington, Seattle, WA, USA. 4. University of Ottawa, Ottawa, ON, Canada. 5. Thrombosis and Hemostasis Center, Division of Hematology, Duke University Medical Center, Durham, NC, USA. 6. University of California, Sacramento, CA, USA. 7. Roswell Park Cancer Institute, Buffalo, NY, USA. 8. Division of Medical Oncology/Department of Medicine, University of Washington, Seattle, WA, USA.
Abstract
BACKGROUND:Ambulatory cancer patients at high-risk for venous thromboembolism (VTE) can be identified using a validated risk score (Khorana score). We evaluated the benefit of outpatient thromboprophylaxis with dalteparin in high-risk patients in a multicenter randomized study. METHODS:Cancer patients with Khorana score≥3 starting a new systemic regimen were screened for VTE and if negative randomized to dalteparin 5000units daily or observation for 12weeks. Subjects were screened with lower extremity ultrasounds every 4weeks on study and with chest CT at 12weeks. The primary efficacy endpoint was all VTE over 12weeks and primary safety endpoint was clinically relevant bleeding events over 13weeks. The study was terminated early due to low accrual. RESULTS: Of 117 enrolled patients, 10 (8.5%) had VTE on baseline screening and were not randomized. Of 98 randomized patients, VTE occurred in 12% (N=6/50) of patients on dalteparin and 21% (N=10/48) on observation (hazard ratio, HR 0.69, 95% CI 0.23-1.89). Major bleeding was similar (N=1) in each arm but clinically relevant bleeding was higher in dalteparin arm (N=7 versus 1 on observation) (HR=7.0, 95% CI 1.2-131.6). There was no difference in overall survival. CONCLUSIONS: Thromboprophylaxis is associated with a non-significantly reduced risk of VTE and significantly increased risk of clinically relevant bleeding in this underpowered study. The Khorana score successfully identifies patients with high incidence of VTE both at baseline and during treatment. Future studies should continue to focus on risk-adapted approaches to reduce the burden of VTE in cancer. TRIAL REGISTRATION: clinicaltrials.gov identifier: NCT00876915.
RCT Entities:
BACKGROUND: Ambulatory cancerpatients at high-risk for venous thromboembolism (VTE) can be identified using a validated risk score (Khorana score). We evaluated the benefit of outpatient thromboprophylaxis with dalteparin in high-risk patients in a multicenter randomized study. METHODS:Cancerpatients with Khorana score≥3 starting a new systemic regimen were screened for VTE and if negative randomized to dalteparin 5000units daily or observation for 12weeks. Subjects were screened with lower extremity ultrasounds every 4weeks on study and with chest CT at 12weeks. The primary efficacy endpoint was all VTE over 12weeks and primary safety endpoint was clinically relevant bleeding events over 13weeks. The study was terminated early due to low accrual. RESULTS: Of 117 enrolled patients, 10 (8.5%) had VTE on baseline screening and were not randomized. Of 98 randomized patients, VTE occurred in 12% (N=6/50) of patients on dalteparin and 21% (N=10/48) on observation (hazard ratio, HR 0.69, 95% CI 0.23-1.89). Major bleeding was similar (N=1) in each arm but clinically relevant bleeding was higher in dalteparin arm (N=7 versus 1 on observation) (HR=7.0, 95% CI 1.2-131.6). There was no difference in overall survival. CONCLUSIONS: Thromboprophylaxis is associated with a non-significantly reduced risk of VTE and significantly increased risk of clinically relevant bleeding in this underpowered study. The Khorana score successfully identifies patients with high incidence of VTE both at baseline and during treatment. Future studies should continue to focus on risk-adapted approaches to reduce the burden of VTE in cancer. TRIAL REGISTRATION: clinicaltrials.gov identifier: NCT00876915.
Authors: Ingrid Pabinger; Nick van Es; Georg Heinze; Florian Posch; Julia Riedl; Eva-Maria Reitter; Marcello Di Nisio; Gabriela Cesarman-Maus; Noémie Kraaijpoel; Christoph Carl Zielinski; Harry Roger Büller; Cihan Ay Journal: Lancet Haematol Date: 2018-06-07 Impact factor: 18.959
Authors: A J Muñoz Martín; E Gallardo Díaz; I García Escobar; R Macías Montero; V Martínez-Marín; V Pachón Olmos; P Pérez Segura; T Quintanar Verdúguez; M Salgado Fernández Journal: Clin Transl Oncol Date: 2020-01-24 Impact factor: 3.405
Authors: Nicole M Kuderer; Marek S Poniewierski; Eva Culakova; Gary H Lyman; Alok A Khorana; Ingrid Pabinger; Giancarlo Agnelli; Howard A Liebman; Eric Vicaut; Guy Meyer; Frances A Shepherd Journal: Oncologist Date: 2017-09-26
Authors: Lara A Kahale; Maram B Hakoum; Ibrahim G Tsolakian; Charbel F Matar; Maddalena Barba; Victor E D Yosuico; Irene Terrenato; Francesca Sperati; Holger Schünemann; Elie A Akl Journal: Cochrane Database Syst Rev Date: 2017-12-29
Authors: Jeffrey I Zwicker; Benjamin L Schlechter; Jack D Stopa; Howard A Liebman; Anita Aggarwal; Maneka Puligandla; Thomas Caughey; Kenneth A Bauer; Nancy Kuemmerle; Ellice Wong; Ted Wun; Marilyn McLaughlin; Manuel Hidalgo; Donna Neuberg; Bruce Furie; Robert Flaumenhaft Journal: JCI Insight Date: 2019-02-21